Redefining critical illness

[1]  Eurie L. Hong,et al.  Whole-genome sequencing reveals host factors underlying critical COVID-19 , 2022, Nature.

[2]  Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. , 2022, Nature medicine.

[3]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[4]  J. Schuurs-Hoeijmakers,et al.  Presence of Genetic Variants Among Young Men With Severe COVID-19. , 2020, JAMA.

[5]  Inkyung Jung,et al.  Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 , 2020, Science Immunology.

[6]  Jeremy C. Weiss,et al.  Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. , 2019, JAMA.

[7]  A. Randolph,et al.  The acute respiratory distress syndrome. , 1996, New England Journal of Medicine.

[8]  M. Matthay,et al.  Heterogeneity in sepsis: new biological evidence with clinical applications , 2019, Critical Care.

[9]  L. Steuten,et al.  Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical Trial , 2018, JAMA.

[10]  J. Marshall,et al.  Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial , 2018, JAMA.

[11]  Boreom Lee,et al.  Prediction and early detection of delirium in the intensive care unit by using heart rate variability and machine learning , 2018, Physiological measurement.

[12]  L. Dirix,et al.  Emerging trends in the treatment of advanced basal cell carcinoma. , 2017, Cancer treatment reviews.

[13]  Gilles Clermont,et al.  Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness , 2017, Critical Care.

[14]  David M. Maslove,et al.  A path to precision in the ICU , 2017, Critical Care.

[15]  J. Kenneth Baillie,et al.  Treatable traits and therapeutic targets: Goals for systems biology in infectious disease , 2017, Current Opinion in Systems Biology.

[16]  A. Khera,et al.  Mendelian Randomization. , 2017, JAMA.

[17]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[18]  J. D. Watson,et al.  Human Genome Project: Twenty-five years of big biology , 2015, Nature.

[19]  J. Connor,et al.  The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.

[20]  G. Bernard,et al.  Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. , 2014, Chest.

[21]  Holger Fröhlich,et al.  Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes , 2014, Nature Communications.

[22]  J. Marshall.  Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[23]  H. Wong,et al.  Gene expression profiling in sepsis: timing, tissue, and translational considerations. , 2014, Trends in molecular medicine.

[24]  J. Marshall,et al.  The PIRO (predisposition, insult, response, organ dysfunction) model , 2013, Virulence.

[25]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[26]  D. Maslove,et al.  Identification of sepsis subtypes in critically ill adults using gene expression profiling , 2012, Critical Care.

[27]  John D. Storey,et al.  A genomic storm in critically injured humans , 2011, The Journal of experimental medicine.

[28]  E. Abraham,et al.  Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? , 2010, Intensive Care Medicine.

[29]  Atul J Butte,et al.  Identification of complex metabolic states in critically injured patients using bioinformatic cluster analysis , 2010, Critical care.

[30]  Robert J Freishtat,et al.  BMC Medicine BioMed Central , 2009 .

[31]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[32]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .